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Abstract
The 2015–2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infec-
tion, followed by protective immunity. The timing and burden of the next Zika virus outbreak
remains unclear. We used an agent-based model to simulate the dynamics of age-specific
immunity to ZIKV, and predict the future age-specific risk using data from Managua, Nicara-
gua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immu-
nity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The
imbalance in age-specific immunity implies that people in the 15–29 age range will be at
highest risk of infection during the next ZIKV outbreak, increasing the expected number of
congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the
maximum benefit in reducing the population-level risk of infection and the risk of adverse
congenital outcomes. This urgency increases if immunity is not lifelong.
Author summary
Zika virus (ZIKV) caused a major outbreak in the Americas between 2015–2017. It
remains unclear if immunity after infection offers life-long protection at an individual
level and how long herd immunity can protect a population against a new ZIKV outbreak.
Data from Managua, Nicaragua showed an imbalance in protective immunity after ZIKV
infection across different age-strata. We used this data to parameterize an individual based
mathematical model to predict the future risk of a new ZIKV outbreak and to evaluate the
effect of loss of immunity and the introduction of vaccination. We found that the 15–29
age range will be at highest risk of infection during the next ZIKV outbreak, increasing the
expected number of congenital abnormalities. We show that vaccination could curb the
risk of infection and could extend the herd immunity, but introduction within the next
decade is crucial to provide the most benefit.
Introduction
Zika virus (ZIKV) is a flavivirus, which is transmitted primarily by mosquitoes of the genus
Aedes. Before 2007, circulation of the virus only occurred sporadically in African and Asian
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countries [1, 2]. Between 2007 and 2013, ZIKV caused large-scale epidemics in the populations
of Micronesia [3], French Polynesia [4] and other Pacific islands [1]. ZIKV probably became
established in Aedes aegypti mosquitoes in the Americas between 2013-2014, [5, 6] and then
spread rapidly across the continent. In 2015, doctors in Brazil started reporting clusters of
infants born with microcephaly, a severe congenital abnormality, and of adults with Guillain-
Barre´ syndrome, a paralyzing neurological condition, resulting in the declaration by the
World Health Organization (WHO) of a Public Health Emergency of International Concern
(PHEIC) [7]. WHO stated, in September 2016, that ZIKV in pregnancy was the most likely
cause of the clusters of microcephaly, and other adverse congenital outcomes [8, 9]. The risk of
an affected pregnancy appears highest during the first trimester, with estimates between 1.0
and 4.5% [10, 11]. By the beginning of 2018, over 220,000 confirmed cases of ZIKV infection
had been reported from Latin America and the Caribbean [12], which is estimated to be only
1.02% (± 0.93%) of the total number of cases, based on mathematical modelling studies [6].
Protective immunity conferred by infection, combined with high attack rates and herd
immunity, can explain the ending of epidemics and the lack of early recurrence [13], as has
been seen with ZIKV [14]. The duration of protective immunity induced by ZIKV infection
remains uncertain, since immunity to ZIKV infection was not studied extensively before the
2013 outbreaks. Evidence from seroprevalence studies in French Polynesia and Fiji found that
levels of ZIKV neutralizing antibodies decrease with time [15]. If the fall in antibody levels
means that people become susceptible to infection again, population level ZIKV immunity
might be declining already. Even if protective immunity is lifelong, the risk of a new ZIKV
outbreak will rise as susceptible newborns replace older individuals, lowering the overall pro-
portion of the population that is immune. A modelling study, based on data from the 2013 epi-
demic in French Polynesia, estimated that ZIKV outbreaks are unlikely to occur for 12 to 20
years, assuming lifelong immunity [16].
A direct consequence of population renewal will be an unequal distribution of immunity by
age group, with younger age groups at higher risk from a new epidemic than older people [14].
That effect will be amplified if ZIKV attack rates are lower in children than adults. Assessing
the risk of ZIKV infection in women of reproductive age is essential because ZIKV infection in
pregnancy, leading to adverse congenital outcomes, has such important implications for indi-
viduals, for public health and for investment in surveillance and mitigation strategies, includ-
ing vector control, early warning systems, and vaccines [17, 18]. However, no vaccine is
currently available against ZIKV. Phase I clinical trials of ZIKV candidate vaccines have shown
levels of neutralizing antibody titers that were considered protective against reinfection [19,
20]. Some vaccines have already entered phase II trials [21], but some companies have stopped
vaccine development [22].
Researchers in Managua, Nicaragua were the first to report the age-stratified seroprevalence
of ZIKV antibodies in population-based surveys [23]. The first cases of autochthonous ZIKV
infection in Nicaragua were reported in January, 2016, and an epidemic was observed between
July and December of that year. Through case-based surveillance, the public health authorities
of Nicaragua reported a total of 2,795 people with ZIKV detected by reverse transcriptase
(RT) PCR over this period [12]. The number of symptomatic infections is likely much higher,
owing to under-reporting. Furthermore, ZIKV infection is asymptomatic in 33 to 87% of cases
[23], which are generally not identified by surveillance systems. Shortly after the end of the
2016 epidemic, Zambrana et al. analyzed sera from two large population-based surveys in
Managua to measure the prevalence of IgG antibodies against ZIKV in 2- to 14-year olds
(N = 3,740) and 15- to 80-year olds (N = 2,147) [23]. The authors reported ZIKV seropreva-
lence of 36.1% (95% confidence interval, CI: 34.5; 37.8%) among the 2-14 year age group and
56.4% (95% CI: 53.1; 59.6%) among the 15-80 year age group [23, 24]. The observed post-
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outbreak seroprevalence in adults is in line with findings from seroprevalence studies from
French Polynesia, Brazil, and Bolivia [25–27].
In this study, we used published data from the 2016 ZIKV epidemic in Managua and devel-
oped an agent-based model (ABM) to predict the evolution of age-specific protective immu-
nity to ZIKV infection in the population of Managua, Nicaragua during the period 2017–2097.
We assessed: 1) the risk of a future ZIKV outbreak; 2) the consequences of a future ZIKV out-
break on women of reproductive age; 3) the influence of loss of immunity on future attack
rates; and 4) how vaccination could prevent future ZIKV outbreaks.
Materials and methods
Modelling strategy
We assessed the consequences of future outbreaks of ZIKV infection in Managua, Nicaragua
using a stochastic ABM. The model follows a basic susceptible-infected-recovered (SIR) frame-
work and integrates processes related to ZIKV transmission, immunity, demography, adverse
congenital outcomes and vaccination (Table 1). We parameterized the model based on pub-
lished estimates or inferences from data about the 2016 ZIKV epidemic (Table 1, Supporting
information S1). We considered different scenarios about the duration of immunity, the tim-
ing and scale of ZIKV reintroductions in the population, and the timing and scale of a hypo-
thetical vaccination program targeted towards 15 year old girls.
Table 1. Parameterization of the agent-based model.
Parameter Comment Source
ZIKV epidemic parameters
Transmission ratea Inferred from the 2016 epidemicb [23]
Recovery rate Inferred from the 2016 epidemicb [23]
ZIKV immunity
Initial immunitya Inferred from the 2016 epidemicb [23]
Duration of immunity Lifelong or decaying with time 5 scenariosc
Demography
Initial age distribution – [28]
Birth rate – [28]
Death ratea – [29]
Ageing Linear ageing at each time-step –
ZIKV reintroduction
Delay until reintroduction 1 to 80 years 80 scenariosc
Cases reintroduced 1, 5 or 10 cases 3 scenariosc
Risk of adverse congenital event
Exposure Proportion of women in the first semester of pregnancy [28]
Risk of microcephaly Upon infection during exposure time (3 levels of risk) [10, 11]
Targeted vaccination
Date of implementation In 2021, 2025 or 2031 3 scenariosc
Effective coverage Proportion of 15 year old girls vaccinated (0% to 80%) 5 scenariosc
aage-dependent parameters;
binferred from the 2016 epidemic by fitting a compartmental SIR model to these data, see Supporting information S1;
cthe different scenarios are discussed in the text in detail under the headings corresponding to the headings of this
table.
https://doi.org/10.1371/journal.pntd.0007978.t001
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Model structure
We simulated a population of 10,000 individuals for 80 years (2017–2097). We assigned agents’
age and ZIKV infection status (susceptible S, infected I or immune R). Initial conditions
reflected the situation in Managua, Nicaragua in 2017, when there was no documentation of
active transmission. In the outbreak-free period, we only considered demographic and immu-
nity processes: births, deaths, ageing and, if applicable, loss of immunity and vaccination.
Given the scarcity of these events at the individual level, we selected a long time-step of seven
days and stochastically applied the transition probabilities at each time step for each agent.
After a given time, ZIKV-infected cases were reintroduced in the population. Upon reintro-
duction, the time step was reduced to 0.1 days, and we evaluated the epidemic-related transi-
tion probabilities: Susceptible agents may become infected at a rate βaI/N, where βa is the age-
dependent transmission rate and N the total population size. Infected individuals may recover
with a rate γ. We ignored the influence of the vector population and assumed that the force of
infection is directly proportional to the overall proportion of infected individuals. We allowed
six months for the outbreak to finish after introduction. Simulations were conducted indepen-
dently for each combination of scenarios and repeated 1,000 times. In the baseline scenario, we
assumed no vaccination, no loss of immunity and a reintroduction of 10 infected individuals.
We implemented the model in ‘Stan’ version 2.18 [30] and we conducted analyses with R
version 3.5.1 [31]. The Bayesian inference framework Stan permits the use of probability distri-
butions over parameters instead of single values, allowing for the direct propagation of uncer-
tainty. Stan models are compiled in C++, which improves the efficiency of simulations. The
algorithm in Supporting information S1 describes the ABM in pseudo code. The model code
and data are available from http://github.com/ZikaProject/SeroProject.
Parameterization
ZIKV epidemic parameters. We inferred the probability distributions for the age-specific
transmission rate βa and the recovery rate γ from data on the 2016 ZIKV epidemic in Mana-
gua, Nicaragua. We used surveillance data [23], which give weekly numbers of incident ZIKV
infections, confirmed by RT-PCR (dataset A, n = 1,165), and survey data on age-stratified
ZIKV seroprevalence, measured among participants of pediatric and household cohort studies
in Managua during weeks 5–32 of 2017 (dataset B, n = 3,740 children and 1,074 adults) [23].
We conducted statistical inference using a deterministic, ordinary differential equation
(ODE)-based version of the ABM with three compartments (S, I and R) and two age classes
(a 2 {1, 2} corresponding to ages 0–14 and�15):
dSa
dt
¼   baSa
P
Ia
N
ð1Þ
dIa
dt
¼ baSa
P
Ia
N
  gIa ð2Þ
dRa
dt
¼ gIa ð3Þ
We ignored demography in this model because it covers a short time span. We recorded
the overall cumulative incidence of ZIKV cases using a dummy compartment:
dC
dt
¼
X
a
baSa
P
Ia
N
ð4Þ
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in order to compute the weekly incidence on week t:
Dt ¼ CðtÞ   Cðt   1Þ ð5Þ
We fitted the model to weekly incidence data A using a normal likelihood after a square-
root variance-stabilizing transformation [32]:
Pr ðAjba; g; r; sÞ ¼
Y
t
N ð
ffiffiffiffi
A
p
j
ffiffiffiffiffiffi
rD
p
; sÞ ð6Þ
where ρ is a reporting rate parameter and σ an error parameter. In addition, we also fitted the
model to the number of individuals with anti-ZIKV antibodies at the end of the epidemic by
age group Ba using a binomial likelihood:
Pr ðBjba; gÞ ¼
Y
a
BðBajna; paÞ ð7Þ
where Ba the number of individuals with antibodies, na is the sample size in each age group,
and pa = Ra(tend)/Na(tend) the proportion of immune at the end of the epidemic. The full likeli-
hood was obtained by multiplying Eqs 6 and 7. We chose weakly-informative priors for all
parameters and fitted the model in Stan (Table 2). We describe the calculation of the basic
reproduction numberR0 in Supporting information S1. We used one thousand posterior
samples for βa and γ obtained by Hamiltonian Monte Carlo in the ABM model, ensuring the
propagation of uncertainty of these parameters. In Supporting information S1 we provide a
schematic representation of the models and the information flow. Parameter values can trans-
late from deterministic to agent-based versions of an epidemic model if the time step is small
[33], which was the reason for using a time step of 0.1 days.
ZIKV immunity. We used the deterministic model, described in the previous section, to
infer the proportion of people with protective immunity within each age group at the end of
the 2016 epidemic ~pa. We used one thousand posterior samples of ~pa in the ABM to allow the
propagation of uncertainty. Protective immunity to ZIKV after infection was lifelong in our
first scenario, so the reduction of the overall proportion of immune individuals in the popula-
tion decreased only because of population renewal. Given the absence of evidence about the
duration of immunity to ZIKV, we considered four scenarios assuming exponentially distrib-
uted durations of immunity with means of 15, 30, 60, 90, or 150 years. These values correspond
to a proportion of initially immune agents that loses immunity after 10 years of 55%, 28%,
15%, 11% or 6%, respectively (Supporting information S1).
Demography. We based the initial age distribution of the population on data from the
World Bank [34]. We used age-dependent death rates for 2016 from the World Health Organi-
zation [29]. For births, we computed a rate based on an average birth rate in Nicaragua of 2.2
Table 2. Parameter estimates inferred from incidence and sero-prevalence data on the 2016 ZIKV epidemic in Managua, Nicaragua.
Parameter Interpretation Prior Posterior (median and 95% CrI)
β1 Transmission for age group 0-14 Expon(0.1) 0.19 (0.16; 0.22)
β2 Transmission for age group�15 Expon(0.1) 0.32 (0.30; 0.36)
1/γ Duration of infectious period Gamma(1, 0.1) 4.8 (4.3; 5.4)
ρ Reporting rate Beta(1, 1) 0.24% (0.21; 0.26)
I(0) Initial number of infectious Expon(0.1) 74 (40; 134)
R0 Basic reproduction number – 1.58 (1.56; 1.59)
CrI: Credible interval.
https://doi.org/10.1371/journal.pntd.0007978.t002
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births per woman, which was uniformly distributed over the female reproductive lifespan [28].
We defined the period of reproductive age between 15 and 49 years. The ageing process was
linear, increasing the age of each agent by 7 days at each 7-day time step.
ZIKV reintroduction. We reintroduced ZIKV in the population after a delay of d = {1, . . .,
80} years in independent simulations. We chose this approach rather than continuous reintro-
ductions to remove some of the stochasticity and assess more clearly the association between
immunity decay and risk of an outbreak. As the probability of an extinction of the outbreak
depends on the number of ZIKV cases reintroduced in the population, we considered three dif-
ferent values for the seed (1, 5 or 10 cases) and compared the results (Supporting information
S1). Simulations using continuous reintroductions each year are presented in the Supporting
information S1.
Risk of adverse congenital outcomes. The estimated number of microcephaly cases
resulting from the reintroduction of ZIKV depended on the exposure, i.e. the number of preg-
nant women infected by ZIKV during their first trimester, to which we applied three different
levels of risk, based on published estimates [10, 11]. We obtained the number of ZIKV infec-
tions among women aged 15–49 years from ABM simulations. As gender was not explicitly
considered in the model, we assumed that women represented 50% of the population. We
assumed a uniform distribution of births during the reproductive period, and considered that
the first trimester constituted a third of ongoing pregnancies at a given time. We explored
three different levels of risk of microcephaly in births to pregnant woman with ZIKV infection
during the first trimester, as reported by Zhang et al. (2017), based on data from French Poly-
nesia (0.95%, called low risk) and Brazil (2.19% and 4.52%, called intermediate and high risk,
respectively) [6, 10, 11].
Vaccination. We examined the effects of a potential ZIKV vaccine, given to 15-year-
old-girls. This vaccination strategy was used for rubella virus, which also causes congenital
abnormalities, before the vaccine was included in the measles, mumps and rubella vaccine
given in early childhood [35]. The main objective of vaccination would be the prevention of
adverse congenital outcomes, including microcephaly. We simulated this intervention in
the ABM, assuming vaccine implementation starting in 2021, 2025 or 2031. From that date,
half of the agents reaching age 15, representing females, could transition to immune status
R regardless of their initial status, with an effective vaccination coverage ranging from 20%
to 80%.
Outcome analysis
From the simulations, we collected 1) the evolution of the age-specific ZIKV immunity in the
population; 2) the attack rate resulting from the reintroduction of ZIKV at year d; 3) the age
of newly infected individuals. We fitted a binary Gaussian mixture model to dichotomize the
observed attack rates into either outbreaks or non-outbreaks. We defined the outbreak thresh-
old as the 97.5% upper bound of the lower distribution. This corresponded to a threshold of
1%, so that attack rates�1% were considered as outbreaks. The age structure of newly infected
individuals was used to compute relative risks of infection by age group.
Sensitivity analysis
We explored the effect of seasonality, of changes in vector density, of migration, and of an
endemic circulation of ZIKV on our predictions regarding the attack rate and the proportion
of introductions that result in an outbreak. Different scenarios, methods and assumptions are
provided in Supporting information S2.
Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak
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Results
2016 ZIKV epidemic
The fitted model (Fig 1), resulted in a reporting rate of 0.24% (95% credible interval, CrI: 0.21;
0.26). The transmission rate in the 0-–14 age group was 42% (95% CrI: 35; 48) lower than in
the�15 age group. This corresponded to an overall basic reproduction numberR0 of 1.58
(95% CrI: 1.56; 1.59). The predicted percentage of immune at the end of the epidemic was 36%
(95% CrI: 34; 38) for the 0–14 age group and 53% (95% CrI: 50; 57) for the�15 age group.
Immunity and population
In our forward simulations, the expected population size increased by 42% between 2017 and
2097. Under the assumption that ZIKV infection results in lifelong protective immunity, pop-
ulation renewal will create an imbalance in the proportion immune in different age groups.
We expect the overall proportion of the population with protective immunity to have halved
(from 48% to 24%) by 2051 and to be concentrated among the older age classes (Fig 2A). The
0–14 year old age group will become entirely susceptible by 2031 and the 15–29 year old age
group by 2046.
Future risk of ZIKV outbreak
Reintroductions of ZIKV in the population of Managua are unlikely to develop into sizeable
outbreaks before 2035, 24 years after the 2016 epidemic, assuming lifelong immunity for
individuals infected in 2016 (Fig 2B). After this point, attack rates resulting from ZIKV rein-
troduction will rise steeply. By 2047, we predict that ZIKV reintroductions will have a 50%
probability of resulting in outbreaks with attack rates greater than 1% (Fig 2C). In 2047 the
median attack rate of successful introductions is 3.6% (IQR: 2.0–6.2).
Risk of infection and microcephaly births in women of reproductive age
The differences between age groups in both immunity and transmission will result in a dispro-
portionate burden of infection in the 15–29 year age class. The relative risk of infection in this
Fig 1. Model fit for the 2016 ZIKV epidemic. Model fit for (A) weekly incidence data and (B) post-epidemic sero-prevalence data from the 2016 ZIKV
epidemic in Managua, Nicaragua. Data points are in red and the corresponding model fit (posterior median and 95% credible interval) is in blue.
https://doi.org/10.1371/journal.pntd.0007978.g001
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age group ranges from 1.2 to 1.6, compared with the general population if an outbreak occurs
during the period 2032–2075 (Fig 3A). As most pregnancies occur in this age group, these
women are also the most likely to experience a pregnancy with an adverse outcome. The
increased risk of infection in this group implies that the number of adverse congenital
Fig 2. Future risk of ZIKV outbreaks. (A) The evolution of the immunity status per age group in a population of 10,000 agents for the next 80 years
based on the demographic structure of Nicaragua. (B) Heat map of the distribution of the attack rates resulting from the reintroduction of ZIKV in the
population at each year (1000 simulations for each year). (C) The evolution of the proportion of reintroductions resulting in outbreaks (with a threshold
of 1%) with time (green), proportion of susceptible (orange), and effective reproduction numberRe (purple).
https://doi.org/10.1371/journal.pntd.0007978.g002
Fig 3. Risk of infection and microcephaly births in women of reproductive age. (A) Relative risk of ZIKV infection during a ZIKV outbreak per age
group compared to the general population by year (median, interquartile range). (B) Expected number of additional microcephaly events associated
with ZIKV infection during pregnancy per 100,000 total population according to three different risk scenarios.
https://doi.org/10.1371/journal.pntd.0007978.g003
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outcomes resulting from a ZIKV outbreak during this period is likely to be higher than
expected with a homogeneous distribution of immunity across ages. Assuming different values
for the added risk of microcephaly after a ZIKV infection during the first trimester, we expect
the mean number of additional microcephaly cases due to ZIKV infection resulting from the
reintroduction of the virus in Managua, Nicaragua to reach 1 to 5 cases per 100,000 population
in 2060 (Fig 3B).
Loss of immunity
If protective immunity to ZIKV is not lifelong, the time window before observing a rise in the
attack rates resulting from ZIKV reintroduction will shorten (Fig 4A). For instance, if 15% of
the those who were infected in 2016 lose their immunity after 10 years (a mean duration of
immunity of 60 years), the time until the risk of outbreak upon reintroduction reaches 50%
would be 14 years earlier (2033) than with lifelong immunity (2047). If 55% lose their immu-
nity after 10 years (a mean duration of immunity of 15 years), in 2024, 50% of the introduc-
tions result in an outbreak, and the attack rate in 2047 is 47%. Loss of immunity over time
would reduce the relative risk in the 15–29 year old age group (Fig 4B).
Targeted vaccination
The implementation of a vaccination program targeted towards 15 year old girls between 2021
and 2031 would reduce the risk of infection in women aged 15-29 years and would also indi-
rectly reduce the overall risk of a ZIKV outbreak in the population (Fig 5). If effective vaccine
coverage is 60–80% amongst 15 year old girls, the prolongation of herd immunity could effec-
tively mitigate the overall risk of a ZIKV outbreak in the population. The reduction in the
number of microcephaly cases would then exceed what would be expected by considering only
the direct protection granted by a vaccine to future mothers. A later implementation of the
Fig 4. Loss of immunity. Consequences of alternative scenarios regarding the mean duration of protective immunity (15, 30, 60 and 150 years),
compared with lifelong immunity (thick black line): (A) median attack rate of ZIKV among reintroductions resulting in outbreaks (with a threshold of
1%) and (B) relative risk of ZIKV infection during an outbreak in the 15–29 year age group compared with the general population.
https://doi.org/10.1371/journal.pntd.0007978.g004
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intervention would be less effective, as it becomes more difficult to maintain the herd immu-
nity (Fig 5B).
Sensitivity analysis
We considered additional model features that may impact our predictions in a sensitivity
analysis (Table 3 and Supporting information S2). Accounting for seasonality or for a future
Fig 5. Targeted vaccination. Consequences of implementing a targeted vaccination program among 15-year-old-girls from 2021 onwards with various
levels of effective vaccination coverage (from 20 to 80%) compared with no vaccination (thick black line). (A) relative risk of ZIKV infection during an
outbreak in the 15–29 year age group compared with the general population and (B) attack rate of ZIKV among reintroductions resulting in outbreaks
(median, interquartile range, with a threshold of 1%), when vaccination is introduced from 2021, 2031, 2041, 2051 or 2061 onwards (red vertical line).
https://doi.org/10.1371/journal.pntd.0007978.g005
Table 3. Summary of the impact of features considered in the sensitivity analysis.
Scenario Consequence on the model Years until 50% of reintroductions result in an outbreak (Year) Attack rate in 2047 (IQR)
Baseline – 31 years (2047) 3.6% (2.0–6.2)
Seasonality Increased transmission rate (+12%) 21 years (2037) 15.3% (11.2–18.4)
Increased vector abundance Increased transmission rate (+12%) 21 years (2037) 15.3% (11.2–18.4)
Decreased vector abundance Decreased transmission rate (–12%) 44 years (2050) 1.6% (1.3–2.5)
Migration Influx of susceptible individuals 23 years (2039) 12.7% (8.7–16.2)
Endemicity Continuous reintroductions 23 years (2039) 2.5% (1.7–4.1)
https://doi.org/10.1371/journal.pntd.0007978.t003
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increase in vector abundance would result in higher transmission rates. This would lead to a
shorter time window until a rise in the risk of ZIKV outbreak, and higher overall attack rates.
A future diminution of vector abundance would have the opposite effects. Human migration
from rural areas to Managua, Nicaragua would lead to a sharper decline of protective immu-
nity in the population, also lowering the time window before the next ZIKV outbreak. Finally,
a continuous endemic circulation of ZIKV in the region would increase the probability of an
outbreak early on and lead to more stochasticity.
Discussion
In this mathematical modelling study, we show that a new ZIKV outbreak in Nicaragua would
affect proportionally more women in the young reproductive age range (15–29 years) than the
general population, owing to the age-dependent infection pattern and population renewal.
The risk of a new ZIKV outbreak in Nicaragua, after reintroduction, will remain low before
2035 because of herd immunity, then rise to 50% in 2047. If protective immunity to ZIKV
decays with time, ZIKV recurrence could occur sooner. Timely introduction of targeted vacci-
nation, focusing on females aged 15 years would both reduce the risk of adverse congenital
outcomes and extend herd immunity, mitigating the overall risk of an outbreak and resulting
in lower attack rates if an outbreak occurs.
Strengths and limitations of the study
A strength of our approach is that it allows for the propagation of uncertainty from the initial
data into the risk assessment, by transferring the posterior distributions of the parameters
from the deterministic model fitted to surveillance and seroprevalence data on the 2016 epi-
demic into the ABM used for simulations. Roche et al. showed that, when a sufficiently small
time step was chosen, stochastic and deterministic models using the same parameter values
led to similar results [36]. Additionally, we benefited from the availability of high quality data
from population-based surveys that included participants from age 2 to 80 years in Managua,
Nicaragua. The age-stratified seroprevalence data allowed us to investigate the risk in different
age groups and better assess the evolution of the age-specific immunity, which is crucial when
studying adverse congenital events caused by ZIKV infection during pregnancy.
We chose a simple approach based on an SIR structure, similar to the model used by Netto
et al. (2017), to focus on the dynamics of infection and immunity in the human population
[26]. We did not model vector populations and behavior explicitly, as in some other studies
[14, 16, 37]. This simplification limits the mechanistic interpretation of the epidemic parame-
ters, but provides a phenomenological description of the transmission dynamics. We believe
that this approach is appropriate because our main objective was to determine the risk of an
outbreak after reintroduction of ZIKV, which is mostly influenced by the level of protective
immunity in the human population. We acknowledge that the future occurrence of ZIKV in
the area also depends on the presence of a competent vector. Our choice is supported by sensi-
tivity analyses that show that more complex model structures (delayed SIR and Ross-MacDon-
ald-type models) were not superior to a simple SIR structure in describing the 2016 ZIKV
epidemic of Managua (Supporting information S1). Similarly, Pandey et al. (2013) showed
that additional model complexity does not result in a better description of the dynamics of
transmission of dengue virus (another Aedes-borne virus) in a human population compared
with a SIR model [38]. In our model, the transmission rate (βa) captures both human-mos-
quito and mosquito-human transmission; we assumed a constant transmission rate, as
observed in the 2016 outbreak.
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Despite having modeled the effect of migration on our predictions, uncertainty remains;
factors such as the political instability in Nicaragua could drive migration and influence dis-
ease transmission, as we currently observe in Venezuela and bordering countries [39].
Interpretation in comparison with other studies
This study shows that the lower attack rate of ZIKV in children than in adults will hasten the
emergence of a population that will be fully susceptible to infection, especially if immunity is
not lifelong. The advantage of our approach is that we used the age-specific attack rates to
model the processes of ageing in relation to protective immunity to ZIKV explicitly. Even with
lifelong immunity, our model predicts that children aged 0–14 years will become entirely sus-
ceptible by 2031 and 15–29 year olds by 2046. In future outbreaks, the attack rate will then be
highest amongst 15–29 year olds, including women who will be at risk of ZIKV infection in
pregnancy. If immunity wanes, the time until the next ZIKV outbreak will be reduced and, in
that case, the distribution of infection risk would be more equal across age groups (Fig 4). Sev-
eral authors have studied the time to a next ZIKV outbreak, but none studied the effect of the
loss of immunity over time in relation to age. Assuming lifelong immunity, our estimates of
the time until the risk increases are similar to the 12–20 years before re-emergence estimated
for French Polynesia [16]. Netto et al. (2017) used an SEIR model to show that in Salvador,
Brazil, the effective reproduction number was insufficient to cause a new outbreak during the
“subsequent years” [26]. Lourenc¸o et al. (2017) showed the same for the whole of Brazil: herd
immunity should protect the population from a new outbreak in the coming years [40]. Fergu-
son et al. (2016) concluded that the age distribution of future ZIKV outbreaks will likely differ
and that a new large epidemic will be delayed for “at least a decade” [14].
Other ZIKV vaccination studies confirm our findings. However, they do not show the effect
in risk groups nor assume herd immunity from previous outbreaks as we did; Durham et al.
(2018) showed that immunizing females aged 9 to 49 years with a 75% effective vaccine and a
coverage of 90%, would reduce the incidence of prenatal infections by at least 94% [41]. Simi-
larly, Bartsch et al. (2018) showed that women of childbearing age or young adults would be an
ideal target group for vaccination [42]. Valega-Mackenzie et al. (2018) formulated a vaccina-
tion model for ZIKV transmission that included mosquito and sexual transmission [43]. They
found that vaccination works if high coverage is achieved, both when sexual transmission or
vector-borne transmission is most important.
Implications and future research
Our finding that people in the 15–29 year age range are more at risk of infection implies that
we expect a higher number of congenital abnormalities due to ZIKV infection. Thus, vaccine
development efforts should be increased. Our conclusions are drawn based on data from
Managua, Nicaragua, but should be relevant to many regions in the Americas and the Pacific
that have documented high post-epidemic levels of seropositivity [25–27]. In regions where
ZIKV has not yet caused an epidemic but competent vectors are present, vaccination would be
in place as well. Further age-stratified seroprevalence studies, using sensitive and specific tests
and with longitudinal follow-up, are needed to improve our understanding of ZIKV antibody
distribution in populations and to quantify the duration of immunity. This information will
provide important information to improve mathematical modeling of ZIKV risk.
ZIKV vaccine development faces considerable hurdles. First, the evaluation of vaccine effi-
cacy has stalled because the reduced circulation of ZIKV has reduced the visibility of ZIKV-
associated disease [22]. Second, it remains unclear if neutralizing antibodies induced by
vaccination are sufficient to protect women against vertical transmission and congenital
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abnormalities [44]. Third, it is not clear whether or how vaccine-induced antibodies against
ZIKV will cross-react with other flaviviruses. To move vaccine development forward, we need
to find regions where disease will occur to be able to conduct trials. This requires identifying
populations that are at risk, and implementing surveillance there. These can either be regions
where ZIKV is endemic, or where ZIKV outbreaks are likely to occur; throughout the Americas,
there might be regions that did not experience an outbreak, but do have suitable conditions
such as competent vectors. Conducting vaccine trials in disease outbreaks is complex, but there
are tools to facilitate planning [45]. ZIKV in an endemic setting, such as in Africa and Asia,
could prove a suitable setting as well. However, ZIKV circulation in endemic setting is not well
described and the occurrence of adverse outcomes in this context is less documented [9]. Fur-
ther research in understanding the transmission of the virus in an endemic context is therefore
needed. Similarly, we need to increase the understanding of changes over time in vector abun-
dance and population composition, since these influence the risk of new outbreaks.
Conclusion
Preparedness is vital; the time until the next outbreak gives us the opportunity to be prepared.
The next sizeable ZIKV outbreak in Nicaragua will likely not occur before 2035 but the proba-
bility of outbreaks will increase. Young women of reproductive age will be at highest risk of
infection during the next ZIKV outbreak. Vaccination targeted to young women could curb
the risk of a large outbreak and extend herd immunity. ZIKV vaccine development and licen-
sure are urgent to attain the maximum benefit in reducing the population-level risk of infec-
tion and the risk of adverse congenital outcomes. The urgency of ZIKV vaccine development
increases if immunity is not lifelong.
Supporting information
S1 Text. Supplementary model description.
(PDF)
S2 Text. Sensitivity analysis.
(PDF)
Acknowledgments
Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at
the University of Bern.
Author Contributions
Conceptualization: Michel J. Counotte, Christian L. Althaus, Nicola Low, Julien Riou.
Formal analysis: Michel J. Counotte, Julien Riou.
Funding acquisition: Nicola Low.
Investigation: Michel J. Counotte.
Methodology: Michel J. Counotte, Julien Riou.
Project administration: Michel J. Counotte.
Software: Michel J. Counotte.
Supervision: Nicola Low.
Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007978 December 26, 2019 13 / 16
Validation: Julien Riou.
Visualization: Michel J. Counotte.
Writing – original draft: Michel J. Counotte, Julien Riou.
Writing – review & editing: Christian L. Althaus, Nicola Low, Julien Riou.
References
1. Wikan N, Smith DR. Zika virus: History of a newly emerging arbovirus. Lancet Infect Dis. 2016; 16(7):
e119–e126. https://doi.org/10.1016/S1473-3099(16)30010-X PMID: 27282424
2. Kohl A, Gatherer D. Zika virus: a previously slow pandemic spreads rapidly through the Americas. J
Gen Virol. 2015; 97(2):269–273. https://doi.org/10.1099/jgv.0.000381 PMID: 26684466
3. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika Virus Outbreak on Yap
Island, Federated States of Micronesia. N Engl J Med. 2009; 360(24):2536–2543. https://doi.org/10.
1056/NEJMoa0805715 PMID: 19516034
4. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika Virus, French Polyne-
sia, South Pacific, 2013. Emerg Infect Dis. 2014; 20(6):1085. https://doi.org/10.3201/eid2006.140138
PMID: 24856001
5. Faria NR, Do Socorro Da Silva Azevedo R, Kraemer MUG, Souza R, Cunha MS, Hill SC, et al. Zika
virus in the Americas: Early epidemiological and genetic findings. Science. 2016; 352(6283):345–349.
https://doi.org/10.1126/science.aaf5036 PMID: 27013429
6. Zhang Q, Sun K, Chinazzi M, Pastore Y Piontti A, Dean NE, Rojas DP, et al. Spread of Zika virus in
the Americas. Proc Natl Acad Sci U S A. 2017; 114(22):E4334–E4343. https://doi.org/10.1073/pnas.
1620161114 PMID: 28442561
7. World Health Organization. WHO statement on the first meeting of the International Health Regulations
(2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disor-
ders and neonatal malformations. WHO. 2016;.
8. Krauer F, Riesen M, Reveiz L, Oladapo OT, Martı´nez-Vega R, Porgo TV, et al. Zika Virus Infection as
a Cause of Congenital Brain Abnormalities and Guillain–Barre´ Syndrome: Systematic Review. PLoS
Med. 2017; 14(1):e1002203. https://doi.org/10.1371/journal.pmed.1002203 PMID: 28045901
9. Counotte MJ, Egli-Gany D, Riesen M, Abraha M, Porgo TV, Wang J, et al. Zika virus infection as a
cause of congenital brain abnormalities and Guillain-Barre´ syndrome: From systematic review to living
systematic review. F1000Research. 2018; 7(196):196. https://doi.org/10.12688/f1000research.13704.
1 PMID: 30631437
10. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Associa-
tion between Zika virus and microcephaly in French Polynesia, 2013-15: A retrospective study. Lancet.
2016; 387(10033):2125–2132. https://doi.org/10.1016/S0140-6736(16)00651-6 PMID: 26993883
11. Johansson MA, Mier-Y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of
Microcephaly. Obstet Gynecol Surv. 2016; 71(11):635–636. https://doi.org/10.1097/OGX.
0000000000000386
12. PAHO. PAHO—Cumulative Incidence; 2019. [Online]. Available from: https://www.paho.org/hq/index.
php?option=com_content&view=article&id=12390:zika-cumulative-cases&Itemid=42090&lang=en.
13. Dietz K. Transmission and control of arbovirus diseases. Epidemiology. 1975; 104:104–121.
14. Ferguson NM, Cucunuba´ ZM, Dorigatti I, Nedjati-Gilani GL, Donnelly CA, Basa´ñez MG, et al. Counter-
ing the Zika epidemic in Latin America. Science. 2016; 353(6297):353–354. https://doi.org/10.1126/
science.aag0219 PMID: 27417493
15. Henderson AD, Aubry M, Kama M, Vanhomwegen J, Teissier A, Mariteragi-Helle T, et al. Zika virus
seroprevalence declines and neutralization antibodies wane in adults following outbreaks in French
Polynesia and Fiji. bioRxiv. 2019; p. 578211.
16. Kucharski AJ, Funk S, Eggo RM, Mallet HP, Edmunds WJ, Nilles EJ. Transmission Dynamics of Zika
Virus in Island Populations: A Modelling Analysis of the 2013–14 French Polynesia Outbreak. PLoS
Negl Trop Dis. 2016; 10(5):e0004726. https://doi.org/10.1371/journal.pntd.0004726 PMID: 27186984
17. Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol. 2018; 16(10):594–600.
https://doi.org/10.1038/s41579-018-0039-7 PMID: 29921914
18. World Health Organization. WHO Malaria Vaccine Pipeline Tracker; 2018. [Online]. Available from:
https://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/.
Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007978 December 26, 2019 14 / 16
19. Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, et al. Safety, tolerability,
and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-
label, phase 1 clinical trials. Lancet. 2018; 391(10120):552–562. https://doi.org/10.1016/S0140-6736
(17)33105-7 PMID: 29217376
20. Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, et al. Preliminary
aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine
candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018; 391
(10120):563–571. https://doi.org/10.1016/S0140-6736(17)33106-9 PMID: 29217375
21. National Institute of Allergy and Infectious Diseases. VRC 705: A Zika Virus DNA Vaccine in Healthy
Adults and Adolescents (DNA); 2018. [Online]. Available from: https://clinicaltrials.gov/ct2/show/
NCT03110770.
22. Cohen J. Steep drop in Zika cases undermines vaccine trial. Science. 2018; 361(6407):1055–1056.
https://doi.org/10.1126/science.361.6407.1055 PMID: 30213891
23. Zambrana JV, Bustos Carrillo F, Burger-Calderon R, Collado D, Sanchez N, Ojeda S, et al. Seropreva-
lence, risk factor, and spatial analyses of Zika virus infection after the 2016 epidemic in Managua, Nica-
ragua. Proc Natl Acad Sci. 2018; 115(37):9294–9299. https://doi.org/10.1073/pnas.1804672115 PMID:
30150394
24. Balmaseda A, Stettler K, Medialdea-Carrera R, Collado D, Jin X, Zambrana JV, et al. Antibody-
based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci. 2017; 114
(31):8384–8389. https://doi.org/10.1073/pnas.1704984114 PMID: 28716913
25. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Roche C, et al. Ross river virus seropreva-
lence, French Polynesia, 2014–2015. Emerg Infect Dis. 2017; 23(10):1751–1753. https://doi.org/10.
3201/eid2310.170583 PMID: 28930020
26. Netto EM, Moreira-Soto A, Pedroso C, Ho¨ser C, Funk S, Kucharski AJ, et al. High Zika Virus Seropreva-
lence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. MBio. 2017; 8(6).
https://doi.org/10.1128/mBio.01390-17 PMID: 29138300
27. Saba Villarroel PM, Nurtop E, Pastorino B, Roca Y, Drexler JF, Gallian P, et al. Zika virus epidemiology
in Bolivia: A seroprevalence study in volunteer blood donors. PLoS Negl Trop Dis. 2018; 12(3):
e0006239. https://doi.org/10.1371/journal.pntd.0006239 PMID: 29513667
28. World Bank. World Development Indicators; 2019. [Online]. Available from: https://data.worldbank.org/
indicator/SP.DYN.TFRT.IN?locations=NI.
29. World Health Organization. WHO | By Category | Life Tables by Country—Nicaragua; 2019. [Online].
Available from: http://apps.who.int/gho/data/?theme=main&vid=61180.
30. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A Probabilistic Pro-
gramming Language. J Stat Softw. 2017; 76(1). https://doi.org/10.18637/jss.v076.i01
31. R Core Team, Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria;
2008.
32. Guan Y. Variance stabilizing transformations of Poisson, binomial and negative binomial distributions.
Stat Probab Lett. 2009; 79(14):1621–1629. https://doi.org/10.1016/j.spl.2009.04.010
33. Roche B, Drake JM, Rohani P. An Agent-Based Model to study the epidemiological and evolutionary
dynamics of Influenza viruses. BMC Bioinformatics. 2011; 12(1):87. https://doi.org/10.1186/1471-2105-
12-87 PMID: 21450071
34. World Bank. World Development Indicators; 2019. [Online]. Available from: https://databank.
worldbank.org/data/reports.aspx?source=2&series=SP.POP.TOTL.MA.IN&country=NIC.
35. Vyse AJ, Gay NJ, White JM, Ramsay ME, Brown DWG, Cohen BJ, et al. Evolution of surveillance of
measles, mumps, and rubella in England and Wales: Providing the platform for evidence-based vacci-
nation policy. Epidemiol Rev. 2002; 24(2):125–136. https://doi.org/10.1093/epirev/mxf002 PMID:
12762088
36. Roche B, Drake JM, Rohani P. An Agent-Based Model to study the epidemiological and evolutionary
dynamics of Influenza viruses. BMC Bioinformatics. 2011; 12(1). https://doi.org/10.1186/1471-2105-
12-87
37. Champagne C, Salthouse DG, Paul R, Cao-Lormeau VM, Roche B, Cazelles B. Structure in the vari-
ability of the basic reproductive number (R0) for Zika epidemics in the Pacific islands. Elife. 2016; 5.
https://doi.org/10.7554/eLife.19874 PMID: 27897973
38. Pandey A, Mubayi A, Medlock J. Comparing vector-host and SIR models for dengue transmission.
Math Biosci. 2013; 246(2):252–259. https://doi.org/10.1016/j.mbs.2013.10.007 PMID: 24427785
39. Tuite AR, Thomas-Bachli A, Acosta H, Bhatia D, Huber C, Petrasek K, et al. Infectious disease implica-
tions of large-scale migration of Venezuelan nationals. J Travel Med. 2018; 25(1). https://doi.org/10.
1093/jtm/tay077 PMID: 30192972
Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007978 December 26, 2019 15 / 16
40. Lourenc¸o J, de Lima MM, Faria NR, Walker A, Kraemer MUG, Villabona-Arenas CJ, et al. Epidemiologi-
cal and ecological determinants of Zika virus transmission in an urban setting. Elife. 2017; 6. https://doi.
org/10.7554/eLife.29820 PMID: 28887877
41. Durham DP, Fitzpatrick MC, Ndeffo-Mbah ML, Parpia AS, Michael NL, Galvani AP. Evaluating vaccina-
tion strategies for zika virus in the Americas. Ann Intern Med. 2018; 168(9):621–630. https://doi.org/10.
7326/M17-0641 PMID: 29610863
42. Bartsch SM, Asti L, Cox SN, Durham DP, Randall S, Hotez PJ, et al. What Is the Value of Different Zika
Vaccination Strategies to Prevent and Mitigate Zika Outbreaks? J Infect Dis. 2018.
43. Valega-Mackenzie W, Rı´os-Soto KR. Can Vaccination Save a Zika Virus Epidemic? Bull Math Biol.
2018; 80(3):598–625. https://doi.org/10.1007/s11538-018-0393-7 PMID: 29359251
44. Diamond MS, Ledgerwood JE, Pierson TC. Zika Virus Vaccine Development: Progress in the Face of
New Challenges. Annu Rev Med. 2018; 70(1):121–135. https://doi.org/10.1146/annurev-med-040717-
051127 PMID: 30388054
45. Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, et al. An online decision tree for
vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine. 2019; 37
(31):4376–4381. https://doi.org/10.1016/j.vaccine.2019.06.019 PMID: 31242963
Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007978 December 26, 2019 16 / 16
